174 related articles for article (PubMed ID: 21040574)
1. Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.
Li Z; Dong Z; Myer D; Yip-Schneider M; Liu J; Cui P; Schmidt CM; Zhang JT
BMC Cancer; 2010 Nov; 10():598. PubMed ID: 21040574
[TBL] [Abstract][Full Text] [Related]
2. 14-3-3sigma negatively regulates the cell cycle, and its down-regulation is associated with poor outcome in intrahepatic cholangiocarcinoma.
Kuroda Y; Aishima S; Taketomi A; Nishihara Y; Iguchi T; Taguchi K; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Jul; 38(7):1014-1022. PubMed ID: 17391729
[TBL] [Abstract][Full Text] [Related]
3. 14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2.
Chen Y; Li Z; Dong Z; Beebe J; Yang K; Fu L; Zhang JT
Mol Cancer Res; 2017 Apr; 15(4):418-428. PubMed ID: 28087741
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms.
Hustinx SR; Fukushima N; Zahurak ML; Riall TS; Maitra A; Brosens L; Cameron JL; Yeo CJ; Offerhaus GJ; Hruban RH; Goggins M
Cancer Biol Ther; 2005 May; 4(5):596-601. PubMed ID: 15908786
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis.
Guweidhi A; Kleeff J; Giese N; El Fitori J; Ketterer K; Giese T; Büchler MW; Korc M; Friess H
Carcinogenesis; 2004 Sep; 25(9):1575-85. PubMed ID: 15073049
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
Schultz J; Ibrahim SM; Vera J; Kunz M
Mol Cancer; 2009 Jul; 8():53. PubMed ID: 19642975
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.
Han B; Xie H; Chen Q; Zhang JT
Mol Cancer Ther; 2006 Apr; 5(4):903-12. PubMed ID: 16648560
[TBL] [Abstract][Full Text] [Related]
8. Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.
Motokura T; Nakamura Y; Sato H
BMC Cancer; 2007 Nov; 7():217. PubMed ID: 18036248
[TBL] [Abstract][Full Text] [Related]
9. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.
Yang H; Zhang Y; Zhao R; Wen YY; Fournier K; Wu HB; Yang HY; Diaz J; Laronga C; Lee MH
Oncogene; 2006 Aug; 25(33):4585-94. PubMed ID: 16532026
[TBL] [Abstract][Full Text] [Related]
10. Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3sigma and CDKN1A (p21) knockout cell lines.
Chu K; Teele N; Dewey MW; Albright N; Dewey WC
Radiat Res; 2004 Sep; 162(3):270-86. PubMed ID: 15332997
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers.
Horie-Inoue K; Inoue S
Semin Cancer Biol; 2006 Jun; 16(3):235-9. PubMed ID: 16682214
[TBL] [Abstract][Full Text] [Related]
12. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
13. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.
Su CH; Zhao R; Zhang F; Qu C; Chen B; Feng YH; Phan L; Chen J; Wang H; Wang H; Yeung SC; Lee MH
Cancer Res; 2011 Feb; 71(3):884-94. PubMed ID: 21135113
[TBL] [Abstract][Full Text] [Related]
14. p73-dependent induction of 14-3-3sigma increases the chemo-sensitivity of drug-resistant human breast cancers.
Sang M; Li Y; Ozaki T; Ono S; Ando K; Yamamoto H; Koda T; Geng C; Nakagawara A
Biochem Biophys Res Commun; 2006 Aug; 347(1):327-33. PubMed ID: 16814250
[TBL] [Abstract][Full Text] [Related]
15. Cooperative effect of p21Cip1/WAF-1 and 14-3-3sigma on cell cycle arrest and apoptosis induction by p14ARF.
Hemmati PG; Normand G; Gillissen B; Wendt J; Dörken B; Daniel PT
Oncogene; 2008 Dec; 27(53):6707-19. PubMed ID: 18806827
[TBL] [Abstract][Full Text] [Related]
16. A structural basis for 14-3-3sigma functional specificity.
Wilker EW; Grant RA; Artim SC; Yaffe MB
J Biol Chem; 2005 May; 280(19):18891-8. PubMed ID: 15731107
[TBL] [Abstract][Full Text] [Related]
17. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
[TBL] [Abstract][Full Text] [Related]
18. Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis.
Zheng G; Peng F; Ding R; Yu Y; Ouyang Y; Chen Z; Xiao Z; He Z
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1477-88. PubMed ID: 20700687
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of 14-3-3sigma influences telomere behavior and ionizing radiation-induced chromosomal instability.
Dhar S; Squire JA; Hande MP; Wellinger RJ; Pandita TK
Mol Cell Biol; 2000 Oct; 20(20):7764-72. PubMed ID: 11003671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
